Table 1 FDA approvals of PARP inhibitors in cancer therapies
Name | Manufacturer | FDA approvals | Trial | |
|---|---|---|---|---|
Olaparib (Lynparza) | AstraZeneca | Ovarian | 2014—Olaparib capsules in patients with BRCA1/2 mutant advanced-stage ovarian cancers who have received \(\ge\) 3 types of chemotherapies | Phase II trial study (Kaufman et al. 2015) |
2017—Maintenance therapy for advanced -ovarian cancer patients with PR or CR to platinum-based chemotherapy | SOLO2/ENGOT-Ov21 (NCT01874353) | |||
2018—First line maintenance therapy for patients with BRCA1/2 mutant advanced-stage ovarian cancers | SOLO-1 (NCT01844986) | |||
Breast | 2018—Patients with BRCA1/2 mutant HER2-negative metastatic breast cancer who have been treated with chemotherapy | OlympiAD (NCT02000622) | ||
2022—Patients with BRCA1/2 mutant HER2-negative high-risk early breast cancer who have been treated with adjuvant chemotherapy | OlympiA (NCT02032823) | |||
Pancreatic | 2019—Adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma | POLO (NCT02184195) | ||
Prostate | 2020—Adult patients with HRR gene mutated metastatic castration-resistant prostate cancer | PROfound (NCT02987543) | ||
Rucaparib (Rubraca) | Clovis Oncology | Ovarian | 2016—Patients with BRCA1/2-mutant ovarian cancer refractory to ≥ prior lines of treatment | ARIEL2 (NCT018191344) |
2018—Maintenance treatment of patients with recurrent ovarian cancer | ARIEL3 (NCT01968213) | |||
Prostate | 2020—BRCA-mutated metastatic castration-resistant prostate cancer | TRITON2 (NCT02952534) | ||
Niraparib | Tesaro | Ovarian | 2019—Patients with HR deficiency -positive, advanced ovarian cancer | QUADRA (NCT02354586) |
2020—First-line maintenance treatment of patients with advanced ovarian cancer | PRIMA (NCT02655016) | |||
Talazoparib | Pfizer | Breast | 2018—Patients with germline BRCA-mutated, Her2-negative locally advanced or metastatic breast cancer | EMBRACA (NCT01945775) |